The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kurushina O.V.

Volgograd State Medical University

Dumtsev V.V.

Volgograd State Medical University

Asthenia in young patients and possibilities for its correction

Authors:

Kurushina O.V., Dumtsev V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(5): 133‑137

DOI: 10.17116/jnevro2024124051133

Read: 2232 times

Download PDF (RU)
Contact the author
Table of contents

ASTHENIA IN YOUNG PATIENTS AND POSSIBILITIES FOR ITS CORRECTION
ASTHENIA IN YOUNG PATIENTS AND POSSIBILITIES FOR ITS CORRECTION

To cite this article:

Kurushina OV, Dumtsev VV. Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(5):133‑137. (In Russ.)
https://doi.org/10.17116/jnevro2024124051133

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Factors of depression acco­rding to acti­graphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Prediction and prevention of burnout syndrome in health care professionals in high epidemic risk settings. Russian Journal of Preventive Medi­cine. 2025;(4):51-56
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Abstract:

OBJECTIVE

To investigate the effect of using the drug Brainmax on various manifestations of asthenic syndrome

MATERIAL AND METHODS

30 patients, average age 29 years (20—44 years) took part in the study. The duration of treatment was 15 days. Subjective indicators on the asthenic state scale, hospital anxiety and depression scale, daytime sleepiness scale, as well as objective indicators of the corrective test were analysed.

RESULTS

It was found that after treating patients with Brainmax, the severity of asthenic syndrome, anxiety, and depression significantly decreased, the quality of sleep increased, and the results of the correction test improved.

CONCLUSION

The drug Brainmax can be recommended for the correction of asthenic syndrome in patients with functional diseases of the nervous system.

Keywords:

asthenia
depression
anxiety
Brainmax
treatment

Authors:

Kurushina O.V.

Volgograd State Medical University

Dumtsev V.V.

Volgograd State Medical University

Received:

06.03.2024

Accepted:

09.04.2024

Close metadata

References:

  1. Bateman L, Bested AC, Bonilla HF, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clin Proc. 2021;96(11):2861-2878. https://doi.org/10.1016/j.mayocp.2021.07.004
  2. Gandasegui M, Laka LA, Gargiulo PÁ, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: A neurological entity? Medicina (Kaunas). 2021;57(10):1030. https://doi.org/10.3390/medicina57101030
  3. Kurushina OV, Barulin AE, Babushkin YH, Kurakova EA. Sleep disorders in general medical practice. Bulletin of Volgograd State Medical University. 2013;48(4):3-7. (In Russ.).
  4. Vasenina EE, Gankina OA, Levin OS. Stress, Asthenia, and Cognitive Disorders. Neurosci Behav Physiol. 2022;52(9):1341-1347. https://doi.org/10.1007/s11055-023-01364-1
  5. Kurushina OV, Barulin AE. Central nervous system damage in COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(1):92-97. (In Russ.). https://doi.org/10.17116/jnevro202112101192
  6. Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) — A systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021;57(5):418.  https://doi.org/10.3390/medicina57050418
  7. Richman S, Morris MC, Broderick G, et al. Pharmaceutical interventions in chronic fatigue syndrome: A literature-based commentary. Clin Ther. 2019;41(5):798-805.  https://doi.org/10.1016/j.clinthera.2019.02.011
  8. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178-193.  https://doi.org/10.1016/s0149-2918(03)90023-3
  9. Gerber LH. Cancer-related fatigue: persistent, pervasive, and problematic. Phys Med Rehabil Clin N Am. 2017;28:65-88.  https://doi.org/10.1016/j.pmr.2016.08.004
  10. Nakamura M, Jang IS. Muscarinic M4 receptors regulate GABAergic transmission in rat tuberomammillary nucleus neurons. Neuropharmacology. 2012;63(6):936-944.  https://doi.org/10.1016/j.neuropharm.2012.07.007
  11. Statsenko ME, Turkina SV, Lopushkova YE. New data on a well-known drug: focus on meldonium. Medical Council. 2021;14:110-117. (In Russ.). https://doi.org/10.21518/2079-701X-2021-14-110-117
  12. Lin NH, Gunn DE, Ryther KB, et al. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem. 1997;40(3):385-390.  https://doi.org/10.1021/jm960233u
  13. Olianas MC, Dedoni S, Onali P. Protection from interferon-beta-induced neuronal apoptosis through stimulation of muscarinic acetylcholine receptors coupled to ERK1/2 activation. Br J Pharmacol. 2016;173(19):2910-2928. https://doi.org/10.1111/bph.13570
  14. Pizova NV. Multimodal approach in the treatment of chronic cerebral ischaemia: what should a doctor know? Medical Council. 2020;4:66-73. (In Russ.). https://doi.org/10.21518/2079-701X-2020-4-66-73
  15. Torshin IIu, Gromova OA, Sardaryan IS, Fedotova LE. Comparative chemoresponse analysis of mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1-2):75-83. (In Russ.). https://doi.org/10.17116/jnevro20171171275-84
  16. Klauchek AE, Barulin AE. Complex non-medicamentous correction in the rehabilitation of patients with postinfection asthenia. Effective Pharmacotherapy. 2023;19(4):18-24. (In Russ.).
  17. Kovalchuk VV, Drozdova MS, Nesterin KV. Factors of success and reasons for failure of rehabilitation of stroke patients. New possibilities of neuroprotective therapy. Effective Pharmacotherapy. 2022;18(43):28-36. (In Russ.).
  18. Tanashyan MM, Raskurazhev AA, Zaslavskaya KY, et al. New possibilities of neuroprotective therapy of patients in the acute and early recovery period of ischaemic stroke. Therapeutic Archive. 2022;94(6):748-755. (In Russ.). https://doi.org/10.26442/00403660.2022.06.201743
  19. Tanashyan MM, Raskurazhev AA, Kuznetsova PI, et al. Prospects and possibilities of therapy for patients with asthenic syndrome after new COVID-19 coronavirus infection. Therapeutic Archive. 2022;94(11):1285-1293. (In Russ.). https://doi.org/10.26442/00403660.2022.11.201981
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.